Generate Biomedicines, Inc. Common Stock (GENB) - Total Liabilities
Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has total liabilities worth $110.94 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Generate Biomedicines, Inc. Common Stock (GENB) net asset momentum to track the company's year-over-year net asset growth rate.
Generate Biomedicines, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Generate Biomedicines, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Generate Biomedicines, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mister Car Wash, Inc. Common Stock
NYSE:MCW
|
USA | $2.04 Billion |
|
Harbin Hatou Investment Co Ltd
SHG:600864
|
China | CN¥35.70 Billion |
|
Honasa Consumer Limited
NSE:HONASA
|
India | Rs6.24 Billion |
|
Airport City Ltd
TA:ARPT
|
Israel | ILA8.99 Billion |
|
Dno ASA
OL:DNO
|
Norway | Nkr4.89 Billion |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
China | CN¥184.80 Million |
|
Tongyu Heavy Industry
SHE:300185
|
China | CN¥7.74 Billion |
|
Kfin Technologies Limited
NSE:KFINTECH
|
India | Rs11.01 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Generate Biomedicines, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Generate Biomedicines, Inc. Common Stock worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Generate Biomedicines, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Generate Biomedicines, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $953.38 Million | +0.00% |
| 2024-12-31 | $953.35 Million | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more